# Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

> **NCT07689188** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Harrison Dermatology** · enrollment: 10 (estimated)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **DRUG:** Roflumilast 0.3% topical foam

## Key facts

- **NCT ID:** NCT07689188
- **Lead sponsor:** Harrison Dermatology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2028-03-10
- **Final completion:** 2028-12-10
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689188, "Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07689188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*